Class III Phosphatidylinositol 4-kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2009 Jul 17

PMID 19605471

Citations 113

Authors

Jason Borawski

Philip Troke

Xiaoling Puyang

Veronica Gibaja

Shanchaun Zhao

Craig Mickanin

Juliet Leighton-Davies

Christopher J Wilson

Vic Myer

Ivan Cornellataracido

Jeremy Baryza

John Tallarico

Gerard Joberty

Marcus Bantscheff

Markus Schirle

Tewis Bouwmeester

Joanna E Mathy

Kai Lin

Teresa Compton

Mark Labow

Brigitte Wiedmann

L Alex Gaither

Affiliations

Soon will be listed here.

Abstract

Host factor pathways are known to be essential for hepatitis C virus (HCV) infection and replication in human liver cells. To search for novel host factor proteins required for HCV replication, we screened a subgenomic genotype 1b replicon cell line (Luc-1b) with a kinome and druggable collection of 20,779 siRNAs. We identified and validated several enzymes required for HCV replication, including class III phosphatidylinositol 4-kinases (PI4KA and PI4KB), carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and mevalonate (diphospho) decarboxylase. Knockdown of PI4KA could inhibit the replication and/or HCV RNA levels of the two subgenomic genotype 1b clones (SG-1b and Luc-1b), two subgenomic genotype 1a clones (SG-1a and Luc-1a), JFH-1 genotype 2a infectious virus (JFH1-2a), and the genomic genotype 1a (FL-1a) replicon. In contrast, PI4KB knockdown inhibited replication and/or HCV RNA levels of Luc-1b, SG-1b, and Luc-1a replicons. The small molecule inhibitor, PIK93, was found to block subgenomic genotype 1b (Luc-1b), subgenomic genotype 1a (Luc-1a), and genomic genotype 2a (JFH1-2a) infectious virus replication in the nanomolar range. PIK93 was characterized by using quantitative chemical proteomics and in vitro biochemical assays to demonstrate PIK93 is a bone fide PI4KA and PI4KB inhibitor. Our data demonstrate that genetic or pharmacological modulation of PI4KA and PI4KB inhibits multiple genotypes of HCV and represents a novel druggable class of therapeutic targets for HCV infection.

Citing Articles

Heme oxygenase 1-mediated ferroptosis in Kupffer cells initiates liver injury during heat stroke.

Li R, Wei R, Liu C, Zhang K, He S, Liu Z Acta Pharm Sin B. 2024; 14(9):3983-4000.

PMID: 39309491 PMC: 11413699. DOI: 10.1016/j.apsb.2024.05.007.

Advances in multi-omics research on viral hepatitis.

Xiang Z, Li J, Lu D, Wei X, Xu X Front Microbiol. 2022; 13:987324.

PMID: 36118247 PMC: 9478034. DOI: 10.3389/fmicb.2022.987324.

Calcium-Prolactin Secretion Coupling in Rat Pituitary Lactotrophs Is Controlled by PI4-Kinase Alpha.

Kucka M, Gonzalez-Iglesias A, Tomic M, Previde R, Smiljanic K, Sokanovic S Front Endocrinol (Lausanne). 2022; 12:790441.

PMID: 35058881 PMC: 8764672. DOI: 10.3389/fendo.2021.790441.

Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function.

Bulankina A, Richter R, Welsch C Pathogens. 2022; 11(1).

PMID: 35056049 PMC: 8779051. DOI: 10.3390/pathogens11010102.

Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019.

Wang N, Brickute D, Braga M, Barnes C, Lu H, Allott L Pharmaceutics. 2021; 13(7).

PMID: 34371769 PMC: 8309005. DOI: 10.3390/pharmaceutics13071078.

References

Blight K, McKeating J, Marcotrigiano J, Rice C . Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol. 2003; 77(5):3181-90. PMC: 149761. DOI: 10.1128/jvi.77.5.3181-3190.2003. View

Tu H, Gao L, Shi S, Taylor D, Yang T, Mircheff A . Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology. 1999; 263(1):30-41. DOI: 10.1006/viro.1999.9893. View

Wang C, Gale Jr M, Keller B, Huang H, Brown M, Goldstein J . Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005; 18(4):425-34. DOI: 10.1016/j.molcel.2005.04.004. View

Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y . Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005; 19(1):111-22. DOI: 10.1016/j.molcel.2005.05.014. View

Zunder E, Knight Z, Houseman B, Apsel B, Shokat K . Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008; 14(2):180-92. PMC: 2720137. DOI: 10.1016/j.ccr.2008.06.014. View

Fillebeen C, Muckenthaler M, Andriopoulos B, Bisaillon M, Mounir Z, Hentze M . Expression of the subgenomic hepatitis C virus replicon alters iron homeostasis in Huh7 cells. J Hepatol. 2007; 47(1):12-22. DOI: 10.1016/j.jhep.2007.01.035. View

Aizaki H, Lee K, Sung V, Ishiko H, Lai M . Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts. Virology. 2004; 324(2):450-61. DOI: 10.1016/j.virol.2004.03.034. View

Ahn J, Chung K, Kim D, Won M, Kim L, Kim K . Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J Biochem Mol Biol. 2004; 37(6):741-8. DOI: 10.5483/bmbrep.2004.37.6.741. View

Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S . Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007; 25(9):1035-44. DOI: 10.1038/nbt1328. View

10.

Goldstein J, Brown M . Regulation of the mevalonate pathway. Nature. 1990; 343(6257):425-30. DOI: 10.1038/343425a0. View

11.

Randall G, Panis M, Cooper J, Tellinghuisen T, Sukhodolets K, Pfeffer S . Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A. 2007; 104(31):12884-9. PMC: 1937561. DOI: 10.1073/pnas.0704894104. View

12.

Fillebeen C, Rivas-Estilla A, Bisaillon M, Ponka P, Muckenthaler M, Hentze M . Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem. 2005; 280(10):9049-57. DOI: 10.1074/jbc.M412687200. View

13.

Zhang , Chung , OLDENBURG . A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen. 2000; 4(2):67-73. DOI: 10.1177/108705719900400206. View

14.

De Clercq E . The design of drugs for HIV and HCV. Nat Rev Drug Discov. 2007; 6(12):1001-18. DOI: 10.1038/nrd2424. View

15.

Ridsdale A, Denis M, Gougeon P, Ngsee J, Presley J, Zha X . Cholesterol is required for efficient endoplasmic reticulum-to-Golgi transport of secretory membrane proteins. Mol Biol Cell. 2006; 17(4):1593-605. PMC: 1415298. DOI: 10.1091/mbc.e05-02-0100. View

16.

Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y . Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005; 129(3):1031-41. DOI: 10.1053/j.gastro.2005.06.031. View

17.

Mathy J, Ma S, Compton T, Lin K . Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother. 2008; 52(9):3267-75. PMC: 2533471. DOI: 10.1128/AAC.00498-08. View

18.

Supekova L, Supek F, Lee J, Chen S, Gray N, Pezacki J . Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem. 2007; 283(1):29-36. DOI: 10.1074/jbc.M703988200. View

19.

Liebel U, Starkuviene V, Erfle H, Simpson J, Poustka A, Wiemann S . A microscope-based screening platform for large-scale functional protein analysis in intact cells. FEBS Lett. 2003; 554(3):394-8. DOI: 10.1016/s0014-5793(03)01197-9. View

20.

Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J . A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res. 2007; 67(24):11493-8. DOI: 10.1158/0008-5472.CAN-07-5173. View